# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-20 (automated, scheduled)
**Run type:** Review only — no files modified
**Prepared by:** diabetes-hub-monitor

---

## TL;DR — What's Actionable

1. **AstraZeneca launched a Phase 3 elecoglipron program.** Four elecoglipron trials (NCT07662044, ...109, ...135, ...213) flipped `NOT_YET_RECRUITING → RECRUITING` between the 07-10 and 07-17 snapshots. New oral small-molecule GLP-1 competitor entering Phase 3 — worth a tracker entry and a combination-mapping look. **[Certain — from snapshot diff]**
2. **Core data is 3 days stale.** `clinical_trials_latest.json`, `pubmed_recent_latest.json`, and `hub_monitor_report.md` all last refreshed 2026-07-17. Re-run the baseline scripts to close the gap. **[Certain]**
3. **One cross-domain PubMed paper hits three Tier-relevant domains** (algorithmic discrimination in pediatric T1D — AI/ML × Closed Loop × Health Equity). Flag for review. **[Certain]**
4. **No genuinely new breaking news in the last 7 days.** The big Phase 3 readouts (retatrutide, orforglipron ACHIEVE) are ADA 2026 (June) items, already >4 weeks old. **[Likely]**

---

## File System Status

| File | Last modified | Age | Status |
|------|--------------|-----|--------|
| `hub_monitor_report.md` | 2026-07-17 02:16 | 3 d | Stale |
| `clinical_trials_latest.json` | 2026-07-17 02:05 | 3 d | Stale |
| `pubmed_recent_latest.json` | 2026-07-17 02:06 | 3 d | Stale |
| `literature_gap_data.json` | 2026-07-18 03:11 | 2 d | OK |
| `literature_gap_report.md` | 2026-07-19 09:08 | 1 d | Fresh |

All five expected inputs are present. The last dated monitor report on disk was `monitor_report_2026-07-18.md`, so this is roughly a 2-day cadence gap. The hub monitor's own scan flagged **827 result files older than 14 days** — mostly archival snapshots and dashboards, not a concern, but the three "latest" data files above are the ones that matter and they need a refresh.

**To refresh (run locally):**
```
python baseline_clinical_trials.py
python baseline_pubmed_alerts.py
python hub_monitor.py
```

---

## Clinical Trial Changes (snapshot 2026-07-10 → 2026-07-17)

Trial universe grew **852 → 858** (net +6; 8 added, 2 removed). Category split in the latest snapshot: T1D Cure & Cell Therapy 152, T1D Immunotherapy & Prevention 76, T2D Novel Therapies 147, Diabetes Technology 236, Recently Completed w/ Results 321. **52 trials are Phase 3 and currently RECRUITING.**

### Status changes worth attention

| Trial | Change | Sponsor | Topic |
|-------|--------|---------|-------|
| NCT07662044 / ...109 / ...135 / ...213 | NOT_YET → **RECRUITING** | AstraZeneca | **Elecoglipron Phase 3 program** (oral GLP-1) |
| NCT07668388 | NOT_YET → RECRUITING | Novo Nordisk | Phase 2 dose-comparison |
| NCT07215312 | RECRUITING → ACTIVE_NOT_RECRUITING | Eli Lilly | LY3938577 Phase 2 (enrollment closed) |

The AstraZeneca elecoglipron activation is the single most notable change — a full four-trial Phase 3 program going live in one week signals a serious oral-GLP-1 entrant. Aligns directly with **Tier 1 area #3 (Clinical Trial Intelligence)** and its combination-mapping mandate.

### New trials added (8)

Mostly device/behavioral or already-completed backfills. Of note: NCT07702890 (Gubra A/S, Phase 1/2 first-in-human), NCT07699380 (UW, Phase 2 insulin-sensitivity), NCT07696273 (Indiana, breath-based hypoglycemia sensor). Removed: NCT06650007, NCT07087340.

### Key-organization Phase 3 landscape (RECRUITING)

- **Vertex** — VX-880 (zimislecel) islet-cell therapy, two Phase 3 trials recruiting (NCT06832410 kidney-transplant cohort; NCT04786262 main). Consistent with public reporting that Vertex pulled FDA filing forward to 2026.
- **Eli Lilly** — Baricitinib beta-cell-preservation Phase 3 pair (NCT07222332, NCT07222137); dulaglutide pediatric Phase 3 (NCT06739122).
- **Novo Nordisk** — insulin icodec (NCT07076199), CagriSema (NCT07564414) Phase 3 recruiting.
- **Sana Biotechnology** — no matching active trial in this snapshot.

### Recently posted results

322 completed trials carry posted results; the most recent postings cluster in 2026-Q2 (e.g., NCT04981847 Dietary Guidelines diets 2026-06-15; NCT04066959 emerging-adulthood 2026-05-05). None are unexpected high-signal readouts from key drug programs — mostly behavioral/nutrition/device studies.

---

## PubMed Highlights (snapshot 2026-07-17; 158 unique papers, 30-day lookback)

### Cross-domain papers (highest priority — 12 total)

The one to review first, because it spans three doctrine-relevant domains:

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: a case of pediatric type 1 diabetes* — **Diabetes AI/ML × Closed Loop AP × Diabetes Health Equity.** Directly relevant to Tier 1 areas #5 (AI/ML) and #6 (Health Equity/disparities).

Other multi-domain hits:
- [42419792] Comparative effects of obesity drugs — orforglipron × retatrutide × CagriSema (three key therapies in one paper).
- [42411999] Residual recipient T cells driving T1D post-HSCT — Stem Cell Cure × Immunotherapy.
- [42458730] & [42459212] Multi-omic BMI / precision-nutrition — Microbiome × Multi-Omics (aligns with Tier 1 #1).
- [42453334] Noncoding RNAs for diabetes — Biomarker × LADA.

### Key-therapy mentions (30-day)

| Therapy | Papers (paper_count / total) |
|---------|------------------------------|
| dapagliflozin | 5 / 52 |
| orforglipron | 5 / 10 |
| CagriSema | 5 / 6 |
| retatrutide | 4 / 4 |
| teplizumab | 4 / 4 |
| icodec | 3 / 3 |
| baricitinib | 2 / 2 |
| **zimislecel** | **0 / 0** |

Note: **zimislecel** returns zero PubMed hits despite two active Vertex Phase 3 trials — publications likely still indexed under "VX-880." Worth adding "VX-880" as an alias in the alert query so the therapy isn't missed.

### Volume

Highest-activity domains (by total matches): AI/ML (260), Microbiome (186), GLP-1 New (167), Biomarker (166). Lowest: GLP-1 Pharmacogenomics (1), Epigenetics (5), Drug Repurpose (8) — the low-volume domains overlap with the highest-scoring literature gaps below, which is consistent.

---

## Gap Analysis Summary (report 2026-07-19; 30 domains, 435 pairs)

Top under-researched intersections (all **BRONZE** validation — single analytical source, expert confirmation pending):

| Rank | Intersection | Gap Score | Joint Pubs |
|------|-------------|-----------|-----------|
| 1 | Treg/CAR-T × Neuropathy | 100.0 | 0 |
| 2 | Beta Cell Regen × Health Equity | 100.0 | 0 |
| 3 | Treg/CAR-T × Health Equity | 100.0 | 0 |
| 4 | Glucokinase × Health Equity | 100.0 | 0 |
| 5 | Gene Therapy × LADA | 100.0 | 0 |
| (6) | Drug Repurposing × Health Equity | 100.0 | 0 |

### Alignment with Tier 1 contribution areas

Three of the top gaps pair a therapeutic domain with **Health Equity** (Tier 1 #6, Epidemiological/Disparity analysis), and **Drug Repurposing × Health Equity** is a *double* Tier 1 hit (#4 + #6). These are the strongest candidates for a computational synthesis contribution — we have the data access (PubMed + repurposing networks + public disparity data) and the doctrine explicitly scopes this work. **[Likely]** — gap scores are BRONZE and could be terminology artifacts; verify each with a combined-term PubMed search before committing (per the report's own guidance).

---

## Breaking News (web, last 7 days)

Nothing genuinely new. The prominent 2026 Phase 3 stories — retatrutide triple-agonist, orforglipron ACHIEVE-2/ACHIEVE-3 superiority, amycretin Phase 2 — trace to the **ADA 2026 Scientific Sessions in June**, already reflected (or reflectable) in our trial/PubMed data. No FDA diabetes approval in the past week; Vertex's zimislecel remains at the pre-filing / Phase 3 stage with an accelerated 2026 submission target and possible 2027 availability. **[Likely — absence of evidence; confirm at next ADA/EASD cycle]**

---

## Recommended Actions

1. **Refresh stale data.** Run `baseline_clinical_trials.py`, `baseline_pubmed_alerts.py`, and `hub_monitor.py` — the three "latest" files are 3 days old.
2. **Add AstraZeneca elecoglipron to the tracker** as a new Phase 3 oral-GLP-1 program (NCT07662044/109/135/213), and run it through combination-mapping against existing incretin trials (Tier 1 #3).
3. **Review cross-domain paper [42459945]** (algorithmic discrimination in pediatric T1D) — relevant to AI/ML and Health Equity; candidate for the fairness/equity synthesis thread.
4. **Fix the zimislecel alert gap** — add "VX-880" as a query alias in `baseline_pubmed_alerts.py` so the therapy is tracked despite naming.
5. **Validate the Drug Repurposing × Health Equity gap** with a combined-term PubMed search; if the gap holds, it is a double-Tier-1 computational-synthesis opportunity.
6. **Housekeeping (optional):** 34 daily `agent_state.json.bak_*` files and ~827 aged result files sit in `Analysis/Results/`. Consider archiving snapshots older than 30 days to keep the folder scan-able.

---

*Evidence levels per Research Doctrine v1.0: [Certain] = observed directly in files/diffs; [Likely] = strong inference; gap classifications are BRONZE pending expert validation. No source files were modified in this run.*
